Literature DB >> 11146051

M100,907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial prefrontal cortex.

E A Pehek1, H G McFarlane, K Maguschak, B Price, C P Pluto.   

Abstract

Previous research has suggested that serotonin 5-HT(2A) receptors modulate the functioning of the mesocortical dopamine (DA) pathway. However, the specific role of 5-HT(2A) receptors localized within the medial prefrontal cortex (mPFC) is not known. The present study employed in vivo microdialysis to examine the role of this receptor in the modulation of basal and K(+)-stimulated (Ca(2+)-dependent) DA release. The selective 5-HT(2A) antagonist M100,907 was infused directly into the mPFC of conscious rats. This resulted in a concentration-dependent blockade of K(+)-stimulated DA release. Intracortical application of M100,907 also blocked increases in DA release produced by the systemic administration of the 5-HT(2A/2C) agonist, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI). These findings demonstrate that local 5-HT(2A) antagonism has an inhibitory effect on stimulated, Ca(2+)-dependent DA release. They suggest that cortical 5-HT(2A) receptors potentiate the phasic release of mesocortical DA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11146051     DOI: 10.1016/s0006-8993(00)03004-3

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  34 in total

1.  5-HT2A receptor antagonist M100907 reduces serotonin synthesis: an autoradiographic study.

Authors:  Shu Hasegawa; Maraki Fikre-Merid; Mirko Diksic
Journal:  Brain Res Bull       Date:  2011-10-25       Impact factor: 4.077

Review 2.  Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.

Authors:  Clint E Canal; Drake Morgan
Journal:  Drug Test Anal       Date:  2012-04-19       Impact factor: 3.345

3.  Blockade of 5-HT2A receptors in the medial prefrontal cortex attenuates reinstatement of cue-elicited cocaine-seeking behavior in rats.

Authors:  Lara A Pockros; Nathan S Pentkowski; Sarah E Swinford; Janet L Neisewander
Journal:  Psychopharmacology (Berl)       Date:  2010-11-16       Impact factor: 4.530

4.  Prefrontal serotonin depletion affects reversal learning but not attentional set shifting.

Authors:  H F Clarke; S C Walker; H S Crofts; J W Dalley; T W Robbins; A C Roberts
Journal:  J Neurosci       Date:  2005-01-12       Impact factor: 6.167

Review 5.  Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.

Authors:  Jiri Horacek; Vera Bubenikova-Valesova; Milan Kopecek; Tomas Palenicek; Colleen Dockery; Pavel Mohr; Cyril Höschl
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

6.  Regulation of rat cortical 5-hydroxytryptamine2A receptor-mediated electrophysiological responses by repeated daily treatment with electroconvulsive shock or imipramine.

Authors:  Gerard J Marek
Journal:  Eur Neuropsychopharmacol       Date:  2008-02-21       Impact factor: 4.600

7.  Effect of serotonin depletion on 5-HT2A-mediated learning in the rabbit: evidence for constitutive activity of the 5-HT2A receptor in vivo.

Authors:  A G Romano; J L Quinn; R Liu; K D Dave; D Schwab; G Alexander; V J Aloyo; J A Harvey
Journal:  Psychopharmacology (Berl)       Date:  2005-12-21       Impact factor: 4.530

8.  Stimulation of glutamate receptors in the ventral tegmental area is necessary for serotonin-2 receptor-induced increases in mesocortical dopamine release.

Authors:  E A Pehek; A E Hernan
Journal:  Neuroscience       Date:  2015-01-28       Impact factor: 3.590

9.  The alpha2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats.

Authors:  Svetlana Semenova; Athina Markou
Journal:  Eur Neuropsychopharmacol       Date:  2010-06-03       Impact factor: 4.600

10.  Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.

Authors:  Herbert Y Meltzer; Roger Mills; Stephen Revell; Hilde Williams; Ann Johnson; Daun Bahr; Joseph H Friedman
Journal:  Neuropsychopharmacology       Date:  2009-11-11       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.